Ohmori, Tsukasa
Nagao, Yasumitsu
Mizukami, Hiroaki
Sakata, Asuka
Muramatsu, Shin-ichi http://orcid.org/0000-0002-3185-7790
Ozawa, Keiya
Tominaga, Shin-ichi
Hanazono, Yutaka
Nishimura, Satoshi
Nureki, Osamu
Sakata, Yoichi
Article History
Received: 3 April 2017
Accepted: 1 June 2017
First Online: 23 June 2017
Competing Interests
: T.O. received research funding from Bayer AG. S.M. owns equity in a gene therapy company (Gene Therapy Research Institution) that commercializes the use of AAV vectors for gene therapy applications. All other authors declare no competing financial interests.